Overview

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

Status:
Completed

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

This study evaluates the efficacy of the addiction of Cyclophosphamide to Revlimid-low dose dexamethasone (Rd) in relapsed/refractory Multiple Myeloma patients, who experienced a biochemical progression, without CRAB, during Rd treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione EMN Italy Onlus
Fondazione Neoplasie Sangue Onlus

Treatments:

BB 1101
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide